文献速递膀胱癌与上尿路尿路上皮癌

原致癌物激活与突变特征模拟人尿路上皮体外癌变起始

Procarcinogen Activation and Mutational Signatures Model the Initiation of Carcinogenesis in Human Urothelial Tissues In Vitro.
PubMed 文献 · Eur Urol · 2020-04-27

研究将正常人尿路上皮(NHU)细胞体外分化后暴露于苯并[a]芘(BaP),经CYP1A1激活并全基因组测序,发现BaP诱导的突变特征与吸烟相关COSMIC_SBS4、COSMIC_DBS2和COSMIC ID3相似,首次直接证明BaP在尿路上皮局部激活并启动吸烟相关突变特征;同时KMT2D、KMT2C和CDKN1A显著过突变,提示选择压力。

要点

  • BaP经尿路上皮CYP1A1局部激活,诱导C>A颠换等吸烟相关突变特征。
  • 该模型重现COSMIC_SBS4、COSMIC_DBS2和COSMIC ID3,但缺乏其他常见膀胱癌基因组特征。
  • KMT2D、KMT2C和CDKN1A在模型中显著过突变,提示组织特异性驱动选择。

核心结论

  • BaP在尿路上皮局部激活,启动吸烟相关突变特征,为膀胱癌起始提供直接实验证据。

研究设计与样本

  • 体外克隆扩增分化的人正常尿路上皮(NHU)细胞,暴露于示例原致癌物BaP,并行全基因组DNA测序推导突变特征。

主要发现

  • BaP经内源性细胞色素P450(CYP1A1)激活,产生基因组修饰的NHU细胞。
  • BaP诱导的突变与吸烟相关特征相似,包括以C>A颠换为特征的单碱基和双碱基替换特征(分别为COSMIC_SBS4和COSMIC_DBS2)。
  • 还诱导同聚物区域C缺失的插入/缺失特征(COSMIC ID3)。
  • 模型缺乏其他常见膀胱癌相关基因组特征,提示膀胱癌存在其他主要病因。
  • 组织特异性驱动基因KMT2D、KMT2C和CDKN1A在该模型中显著过突变。

临床怎么用

  • 该体外模型可用于研究尿路上皮癌变起始及吸烟相关突变过程。
  • 提示膀胱癌还存在非吸烟直接相关的未知突变过程,需进一步研究。

局限性

  • 研究为体外细胞模型,不能完全代表体内尿路上皮癌变过程。
  • 突变特征分析不反映基因是否受影响,需结合驱动基因分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Disparity between genome-wide mutations in bladder and other cancers where smoking is a risk factor raises questions about carcinogenesis in different epithelia. To develop an experimental model of bladder carcinogenesis, we clonally expanded in vitro differentiated normal human urothelial (NHU) cells following exposure to an exemplar procarcinogen and used whole-genome DNA sequencing to derive mutational signatures. Benzo[a]pyrene (BaP) was activated by endogenous cytochrome P450 (cytochrome P450 family 1 subfamily A member 1 [CYP1A1]) to create genomically modified NHU cells. Comparison with the Catalogue of Somatic Mutations in Cancer (COSMIC) showed that mutations induced by BaP in NHU cells were similar to smoking-associated signatures in bladder and other cancers, including single- and doublet-base substitution signatures characterised by C > A transversions (COSMIC_SBS4 and COSMIC_DBS2, respectively), and an insertion/deletion signature of C deletions in homopolymer regions (COSMIC ID3). Our study provides the first direct evidence that BaP is activated locally in the urothelium, initiating the well-described smoking-associated mutational signatures. An absence of other common bladder cancer (BLCA)-associated genomic signatures points strongly to other primary causes of BLCA, which the new experimental approach described here is well placed to investigate. Mutational signatures ignore whether genes are affected, but tissue-specific drivers (KMT2D, KMT2C, and CDKN1A) were significantly overmutated in this model, providing insight on the emergent selection pressures. PATIENT SUMMARY: In a carefully controlled laboratory setting, we exposed normal human urothelial tissues to a procarcinogen (benzo[a]pyrene) found in cigarette smoke. We show that the urothelial tissues activated the carcinogen and led to mutations forming across the genome in a characteristic pattern. This particular "mutational signature" is found in bladder tumours and other smoking-induced cancers (eg, lung); however, our study highlights that there are other unknown mutational processes in bladder cancer that is not the direct result of smoke carcinogens, and this will require further investigation.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Baker SC, Mason AS, Southgate J, et al. Procarcinogen Activation and Mutational Signatures Model the Initiation of Carcinogenesis in Human Urothelial Tissues In Vitro. Eur Urol. 2020. PMID: 32349929. doi:10.1016/j.eururo.2020.03.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。